Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
26
27
28
29
30
31
2
3
4
5
6
7
8
9
10
8:30 AM - HIMSS Europe
11
12
13
14
15
16
17
18
19
20
21
22
26
27
28
29
1
2
3
4
5
6
e-Health 2025 Conference and Tradeshow
2025-06-01 - 2025-06-03    
10:00 am - 5:00 pm
The 2025 e-Health Conference provides an exciting opportunity to hear from your peers and engage with MEDITECH.
HIMSS Europe
2025-06-10 - 2025-06-12    
8:30 am - 5:00 pm
Transforming Healthcare in Paris From June 10-12, 2025, the HIMSS European Health Conference & Exhibition will convene in Paris to bring together Europe’s foremost health [...]
38th World Congress on  Pharmacology
2025-06-23 - 2025-06-24    
11:00 am - 4:00 pm
About the Conference Conference Series cordially invites participants from around the world to attend the 38th World Congress on Pharmacology, scheduled for June 23-24, 2025 [...]
2025 Clinical Informatics Symposium
2025-06-24 - 2025-06-25    
11:00 am - 4:00 pm
Virtual Event June 24th - 25th Explore the agenda for MEDITECH's 2025 Clinical Informatics Symposium. Embrace the future of healthcare at MEDITECH’s 2025 Clinical Informatics [...]
International Healthcare Medical Device Exhibition
2025-06-25 - 2025-06-27    
8:30 am - 5:00 pm
Japan Health will gather over 400 innovative healthcare companies from Japan and overseas, offering a unique opportunity to experience cutting-edge solutions and connect directly with [...]
Electronic Medical Records Boot Camp
2025-06-30 - 2025-07-01    
10:30 am - 5:30 pm
The Electronic Medical Records Boot Camp is a two-day intensive boot camp of seminars and hands-on analytical sessions to provide an overview of electronic health [...]
Events on 2025-06-01
Events on 2025-06-10
HIMSS Europe
10 Jun 25
France
Events on 2025-06-23
38th World Congress on  Pharmacology
23 Jun 25
Paris, France
Events on 2025-06-24
Events on 2025-06-25
International Healthcare Medical Device Exhibition
25 Jun 25
Suminoe-Ku, Osaka 559-0034
Events on 2025-06-30
Latest News

Factors Predicting Poor Locoregional Control in Tongue Cancer

In patients with pT1-2N0 oral tongue squamous cell carcinoma undergoing partial glossectomy and elective neck dissection, inferior locoregional control (LRC) was associated with depth of invasion, lymphovascular space invasion, and positive glossectomy specimen margins. These retrospective findings, presented at the 2024 ASTRO Multidisciplinary Head and Neck Cancers Symposium, remained significant even in cases with final negative tumor bed margins.At a median follow-up of 45.6 months, the all-comer patient population exhibited 3-year locoregional control (LRC) and overall survival (OS) rates of 88.0% and 92.5%, respectively. Among patients with pT1 disease, these rates were 92.0% and 95.2%, while in those with pT2 disease, the rates were 85.0% and 90.5%.

However, during the multivariate analysis, individuals with positive glossectomy margins exhibited poorer locoregional control (HR, 6.66; 95% CI, 1.60-27.78; P = .009). Lymphovascular space invasion (HR, 6.90; 95% CI, 1.42-33.65; P = .02) and depth of invasion (HR, 1.31; 95% CI, 1.06-1.63; P = .01) were also correlated with diminished locoregional control.

The lead study author, Michael Modzelewski, MD, along with the co-investigators, stated in a poster presented at the meeting, “Patients with these risk factors may be considered for adjuvant radiotherapy to optimize disease control.”

Individuals with early-stage tongue squamous cell carcinoma typically do not undergo adjuvant radiation due to their low recurrence risk. After surgery, the status of the primary glossectomy specimen margin has been observed to have a stronger correlation with local recurrence than the status of additional tumor bed margins, as stated by the authors.

The investigators aimed to identify the pathological factors associated with locoregional recurrence in patients with early-stage tongue squamous cell carcinoma who underwent surgery alone. Additionally, they explored the impact of a positive glossectomy specimen margin on disease control concerning final negative tumor bed margins.

The research included 110 patients diagnosed with pT1-2N0 oral tongue squamous cancer, adhering to the American Joint Committee on Cancer (AJCC) 8th edition criteria. These individuals underwent partial glossectomy and elective dissection from 2015 to 2021, excluding adjuvant radiation. Pathology reports were examined for factors such as tumor size, depth of invasion, glossectomy specimen margin, final tumor bed margin status, and perineural or lymphovascular space invasion. Individuals with positive final margins or a history of head and neck radiation were excluded.

The Kaplan-Meier method was employed to estimate locoregional control (LRC) and overall survival (OS), with a Cox proportional hazards model identifying prognostic factors for LRC in multivariate analysis.

Concerning baseline characteristics, the median age was 52 years, with the majority being male (54.5%) and having pT2 stage disease (58.2%). There were 33 lymph nodes dissected on average, and the median tumor size measured 16 mm, with a depth of invasion reaching 5 mm.

The majority of patients did not exhibit perineural invasion (84.7%), while 3.6% had lymphovascular space invasion. Positive glossectomy specimen margins were observed in 8.2% of cases.

Further findings revealed that among patients with positive glossectomy specimen margins and those without, the 3-year locoregional control (LRC) rates were 66.7% and 89.5%, respectively. Similarly, the rates were 0.0% for individuals with lymphovascular space invasion and 89.4% for those without. Among the 8 patients experiencing regional failure, 5 had recurrence in the ipsilateral neck alone (62.5%), 2 in the bilateral neck (25.0%), and 1 with isolated contralateral neck recurrence (12.5%).